Hi, what are you looking for?
Jewish Business News
Search results for "Teva Pharmaceutical"
Business
A Credit Suisse study finds that most hostile bids fail, especially if antitrust concerns are involved.
Business
Teva Chairman Yitzhak Peterburgand and Teva’s CEO Erez Vigodman, are pushing Mylan to take Teva’s $40 billion take-over bid offer seriously.
Business
In the three way takeover battle Mylan is getting nervous.
Business
Three Way Takeover Battle: believes their offer will win approval from Perrigo stockholders.
Business
Teva Pharmaceutical Industries Ltd. has agreed to pay $1.2 billion in a settlement with the U.S. Federal Trade Commission (FTC), resolving claims that Cephalon...
Business
Teva Pharmaceutical Industries Ltd, an Israeli-based company, has acquired a 1.35 percent stake in Mylan through purchases on the open market, increasing pressure on...
Business
George Soros’ Soros Fund Management, which currently manages some $30 billion in assets, announced his holdings in filings with the Securities and Exchange Commission,...
Business
Teva CFO Eyal Desheh told Merrill Lynch that it could secure antitrust clearance for the takeover in 4-7 months.
Business
As Israeli pharmaceutical giant Teva pushes ahead with a $40-billion dollar hostile bid for US generic drugmaker Mylan, Brent Saunders, CEO of...
Business
Teva declined the chance because it does not operate in the store-brand OTC market, Perrigo's main activity.